1 |
Ayala-Aguilera, C.C., Valero, T., Lorente-Macias, A., Baillache, D.J., Croke, S., and Unciti-Broceta, A. (2022). Small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis. J. Med. Chem. 65, 1047-1131.
DOI
|
2 |
Chan, J.M., Zaidi, S., Love, J.R., Zhao, J.L., Setty, M., Wadosky, K.M., Gopalan, A., Choo, Z.N., Persad, S., Choi, J., et al. (2022). Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science 377, 1180-1191.
DOI
|
3 |
Heo, Y.J., Hwa, C., Lee, G.H., Park, J.M., and An, J.Y. (2021). Integrative multi-omics approaches in cancer research: from biological networks to clinical subtypes. Mol. Cells 44, 433-443.
DOI
|
4 |
Katoh, M. (2019). Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat. Rev. Clin. Oncol. 16, 105-122.
DOI
|
5 |
Zheng, J., Zhang, W., Li, L., He, Y., Wei, Y., Dang, Y., Nie, S., and Guo, Z. (2022). Signaling pathway and small-molecule drug discovery of FGFR: a comprehensive review. Front. Chem. 10, 860985.
DOI
|
6 |
Zingg, D., Bhin, J., Yemelyanenko, J., Kas, S.M., Rolfs, F., Lutz, C., Lee, J.K., Klarenbeek, S., Silverman, I.M., Annunziato, S., et al. (2022). Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature 608, 609-617.
DOI
|
7 |
Liu, H., Zhang, B., and Sun, Z. (2020). Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis. Cancer Commun. (Lond.) 40, 43-59.
DOI
|